Epsilogen

About Epsilogen

Epsilogen is a pioneering company in the field of antibody therapeutics for cancer treatment. As the world's leading pan-isotype antibody therapeutic company, it focuses on the discovery and development of immunoglobulin IgE, IgA, and IgG-based therapeutics to optimize cancer treatment by matching antibody isotypes to specific cancer challenges.

Products & Services

MOv18 IgE:The world's first therapeutic IgE antibody to enter clinical trials, currently in a Phase Ib study for platinum-resistant ovarian cancer (PROC). It targets folate receptor ⍺ and has shown safety and early clinical activity.

IgE:Ideal for treating solid tumors with enhanced tumor access, long tissue half-life, and the ability to kill cancer cells with low antigen levels. It activates myeloid and T cells, warming the tumor microenvironment, and pairs well with checkpoint inhibitors.

IgA:Activates neutrophils to drive innate and adaptive immunity, harnessing anti-cancer potential.

Bispecific IgE:A platform combining different antibody isotypes into single molecules to enhance anti-cancer potential.

IgEGs:A proprietary platform for developing advanced antibody therapeutics.

Specialties

Immunoglobulin IgE-based therapeutics Immunoglobulin IgA-based therapeutics Immunoglobulin IgG-based therapeutics Pan-isotype antibody development Cancer treatment innovation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 16250000 MR: - FA: £12.5 million FAN: 16250000	D: 2024-09-09 FD: 2024-09-09	5 investors

Series B Latest

2024-09-09

$16.2M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Tim Wilson

Chief Executive Officer

K

Kevin FitzGerald

Chief Scientific Officer

N

Nick Robbins-Cherry

Chief Financial Officer

E

Elizabeth Hardaker

Chief Translational Science Officer

L

Leanne Partington

VP of Product Development

A

Andrew Calam

VP of Clinical Operations

View 13 more team members with Pro

Unlock Full Team Directory

Recent News

Epsilogen Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised